The Hole Between FDA Authorization and Medicare Protection
In April 2026, the Facilities for Medicare & Medicaid Providers (“CMS”) and the U.S. Meals and Drug Administration (“FDA”) introduced a proposed initiative, the Regulatory Alignment for Predictable and Instant System (“RAPID”) pathway, supposed to expedite Medicare protection of sure Class II and Class III units which have acquired Breakthrough System designation and are pursuing FDA market authorization whereas partaking with CMS. Below RAPID, CMS goals to situation a proposed Nationwide Protection Willpower (“NCD”) at or across the time of FDA market authorization for eligible units. Whereas RAPID is meant to speed up Medicare protection assessment, the pathway doesn’t present computerized Medicare protection upon FDA authorization. Somewhat, it initiates the NCD course of on the time of authorization, probably permitting nationwide protection and fee to grow to be efficient roughly 60 to 90 days later.
RAPID is meant to shut the hole in time between FDA’s authorization of latest medical expertise and Medicare protection, which may, in some circumstances, lengthen for a number of years. This delay might have an effect on each affected person entry to progressive applied sciences and producers’ capacity to safe reimbursement certainty following FDA authorization.
One of many principal drivers for this hole is the distinction between FDA’s authorization normal, which requires that the brand new expertise show that it’s “protected and efficient,” and CMS’s normal for Medicare protection, which requires the expertise to be “affordable and mandatory” for the Medicare inhabitants. These requirements ceaselessly require analysis of overlapping however distinct questions. Whereas the FDA focuses on whether or not a tool is protected and efficient for its supposed use, CMS evaluates whether or not the merchandise or service is affordable and mandatory for Medicare beneficiaries, who might differ from populations enrolled in pivotal medical research. Traditionally, CMS assessment has adopted FDA authorization, typically leading to a chronic and resource-intensive course of to acquire each regulatory approval and protection, significantly the place variations in evidentiary necessities between FDA and CMS require producers to generate further information after FDA authorization.
FDA’s Breakthrough Units Program
Part 515B of the Federal Meals, Drug, and Beauty Act, codified at 21 U.S.C. § 360e-3, as added by the 21st Century Cures Act and later amended, established FDA’s Breakthrough Units Program “to assist sufferers have extra well timed entry to medical units by expediting their growth, evaluation and assessment, whereas preserving the statutory requirements for premarket approval, 510(okay) clearance, and De Novo classification, per the Company’s mission to guard and promote public well being.”
Producers might request Breakthrough System designation via a submission to FDA demonstrating that the gadget has the potential to supply simpler remedy or analysis of a life-threatening or irreversibly debilitating human illness or situation, and that it meets a minimum of one of many following standards: 1) represents breakthrough expertise; 2) no authorised or cleared options exist; 3) gives vital benefits over current authorised or cleared options; or 4) gadget availability is in the most effective curiosity of sufferers.
FDA should decide whether or not to grant Breakthrough System designation inside 60 calendar days after receiving a request. FDA classifies medical units into three classes primarily based on the extent of regulatory management mandatory to supply an affordable assurance of security and effectiveness. Class I units are usually lower-risk units topic to common controls, equivalent to bandages, examination gloves and sure easy surgical devices. Class II units current a reasonable threat and are topic to each common and particular controls, equivalent to efficiency requirements, particular labeling necessities or post-market surveillance; examples embrace infusion pumps, X-ray machines, powered wheelchairs and blood glucose meters. Class III units are the highest-risk units and customarily require premarket approval as a result of common and particular controls are inadequate to guarantee security and effectiveness. These units typically help or maintain human life, are of considerable significance in stopping impairment of human well being or current a possible unreasonable threat of sickness or harm, equivalent to coronary heart valves, pacemakers, deep mind stimulators and automatic exterior defibrillators. As of late 2025, FDA had granted greater than 1,200 Breakthrough System designations and licensed greater than 160 such units.
The RAPID program applies solely to eligible Class II and Class III units. Below the RAPID pathway, FDA and CMS intend to coordinate early on medical examine design, together with the usage of Investigational System Exemption research that enroll Medicare beneficiaries and generate medical final result information related to each FDA premarket authorization and CMS protection determinations.
Medicare Protection Requires Project of Cost Codes and Nationwide or Native Protection Determinations
Typically, for Medicare to pay for companies involving a medical gadget, suppliers should report companies utilizing relevant CPT or Healthcare Frequent Process Coding System codes for outpatient companies and applicable fee classes, equivalent to Ambulatory Cost Classifications (“APCs”), together with new expertise APCs for companies that can not be precisely described utilizing current codes. For inpatient companies, procedures are reported utilizing ICD-10-PCS codes. Whereas the task and use of those codes allow suppliers to invoice for companies involving a tool, coding alone doesn’t decide Medicare protection or fee. Medicare fee is obtainable provided that the merchandise or service is set to be “affordable and mandatory” for the analysis or remedy of sickness or harm or to enhance the functioning of a malformed physique member beneath Part 1862(a)(1)(A) of the Social Safety Act, 42 U.S.C. § 1395y(a)(1)(A).
To find out whether or not a specific gadget or process will likely be paid for by Medicare, CMS points nationwide steerage within the type of an NCD, whereas Medicare Administrative Contractors might situation steerage for regional protection generally known as a Native Protection Willpower to help suppliers in submitting claims for fee. CMS doesn’t situation NCDs for all units or procedures; as such, Medicare contractors might write native insurance policies that can lead to variations in protection for Medicare beneficiaries throughout the nation.
Previous Efforts to Scale back Medicare Protection and Cost Points
The event of the brand new RAPID pathway gives the opportunity of enhancements within the FDA authorization and CMS protection processes. On the identical time, there may be purpose to be cautious in assessing whether or not the RAPID pathway will obtain outcomes past prior initiatives by CMS and FDA to deal with these issues. For instance, in 2016 CMS and FDA created two applications; one entitled Parallel Evaluation, which allowed CMS and FDA to assessment medical information of Class III units concurrently, and one other entitled the Early Payor Suggestions Program, which inspired producers to work with protection organizations, equivalent to insurance coverage corporations and well being expertise evaluation teams, to acquire payor enter on medical trial design and different medical proof that would assist help each protection choices and FDA’s willpower {that a} gadget is protected and efficient. These efforts haven’t made vital progress in resolving the coordination situation, as Class III units represented solely a small portion of FDA‑regulated units (roughly 10% of gadget varieties), and these applications didn’t show considerable change within the median approval time for novel applied sciences.
CMS tried once more in 2021, establishing the Medicare Protection of Progressive Expertise program, beneath which CMS promised 4 years of nationwide protection instantly upon FDA market authorization. This program was rescinded inside the identical 12 months because of CMS’s issues relating to inadequate proof to help “affordable and mandatory” determinations for the Medicare inhabitants. Lastly, in 2024, CMS established the Transitional Protection for Rising Applied sciences (“TCET”) pathway. Though TCET was supposed to facilitate extra well timed protection determinations, the pathway has chosen solely a restricted variety of units for participation and has not constantly achieved its purpose of finalizing NCDs inside six months of FDA authorization.
The RAPID pathway is meant to scale back the timeline from FDA authorization to CMS nationwide protection from 9-12 months to 60-90 days. Its program design limits RAPID participation to sure Class II units collaborating within the FDA Complete Product Life Cycle Advisory Program (“TAP”) and Class III units, no matter TAP participation, which, as with prior pathways, might restrict the variety of units eligible for expedited protection. As well as, it stays unclear whether or not current useful resource constraints at FDA and CMS might have an effect on the companies’ capacity to implement this system at scale and obtain its supposed timelines.
CMS has not but finalized the RAPID pathway via formal rulemaking, and additional steerage relating to implementation and public remark alternatives is anticipated.
Sensible Takeaways
- RAPID is meant to permit CMS to start the NCD course of on the time of FDA authorization for eligible Breakthrough Units, probably lowering the time between authorization and Medicare protection.
- The pathway displays elevated coordination between FDA and CMS relating to medical proof growth and assessment.
- RAPID doesn’t remove CMS’s unbiased obligation to find out whether or not a tool is affordable and mandatory for the Medicare inhabitants.
- Whether or not RAPID succeeds the place prior initiatives have struggled will rely upon implementation, useful resource allocation and the companies’ capacity to take care of significant alignment all through the assessment course of.
When you’ve got any questions on this subject or would love help with submitting feedback, please contact:
Corridor Render weblog posts and articles are supposed for informational functions solely. For moral causes, Corridor Render attorneys can not—exterior of an attorney-client relationship—reply particular questions that will be authorized recommendation.